Insights Hub

What’s New. What’s Coming.

Read the latest quarterly reports and get updates about new drugs on the horizon.
Our Latest Insights

2024 Insights Report

Learn more about the top industry and pharmacy trends driving pharmacy plan spend in 2025 and how our clinical programs can help.
Insight Report

GLP-1

GLP-1 medications continue to shape pharmacy trends. Learn more about what is behind the growth of GLP-1 medications used to treat diabetes and weight management. 
Insight Report

Biosimilars

The biosimilar landscape is quickly evolving with the addition of new therapies, allowing for better access, more choice, and lower costs.
Insight Report

Cell and Gene Therapy

Cell and gene therapies are transforming the treatment landscape for many diseases, especially for those which have no effective therapies.
Our Latest Pipelines

Q2 2025 Pipeline Report

Learn about new therapies in the pipeline that can enhance treatment options, with a spotlight on the weight management pipeline.
Pipeline Report

Q1 2025 Pipeline Report

In our Q1 2025 edition, Stelara biosimilars prepare for a Q1 launch, key clinical drugs approach their expected approval dates, and we spotlight the oncology pipeline.
Pipeline Report

Q4 2024 Pipeline Report

In our Q4 2024 edition, FDA tackles Vyvanse® shortages, approves first nasal spray for anaphylaxis, and we spotlight advances in atopic dermatitis treatment.

Learn more about how we can improve your pharmacy experience

Recent News

News

VytlOne and Maury Regional Health Expand Their Pharmacy Services Partnership

VytlOne, a leading provider of pharmacy solutions, is expanding its existing partnership with Maury Regional ...
Read More →
Blog

The rise of long-acting injectable drugs: Changing the way we manage chronic disease

Exploring the benefits and challenges of LAIs in modern medicine Overview In the ever-evolving world ...
Read More →
News

Big news! Maxor is now VytlOne

Maxor Rebrands as VytlOne to Highlight Its Innovative Full-Service Pharmacy Solutions That Drive Revenue, Growth, ...
Read More →
Scroll to Top